SAVA Form 4: 53,000 director stock options granted
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cassava Sciences (SAVA) reported a director stock option grant. On 10/21/2025, the director received a stock option for 53,000 shares with an exercise price of $3.98 per share and an expiration date of 10/21/2035. The option vests over three years at 1/36th each month. Following the grant, 53,000 derivative securities were beneficially owned, held directly. The grant price for the option was reported as $0.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bir Dawn Carter
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 53,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 53,000 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did Cassava Sciences (SAVA) disclose in this Form 4?
A director was granted a stock option for 53,000 shares on 10/21/2025.
What is the exercise price of the new SAVA stock option?
The exercise price is $3.98 per share.
How does the SAVA option vest?
It vests over three years at a rate of 1/36th each month.
When does the SAVA option expire?
The expiration date is 10/21/2035.
How many derivative securities are owned after this transaction?
53,000 derivative securities were beneficially owned following the grant.
Is the ownership recorded as direct or indirect?
The filing lists ownership as Direct (D).